Dr. Andrew S. Brohl, MD

Dr. Brohl practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Brohl's NPI, 1609022870, was assigned on August 7, 2008. Dr. Brohl graduated from University of Miami, Miller School of Medicine in 2006. Dr. Brohl holds Florida license ME124615.

Dr. Brohl's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Brohl also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Brohl's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Brohl to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brohl practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Brohl's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Brohl is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Brohl's licenses on file in 4 states: Florida, New York, Virginia and District of Columbia.

CMS data shows 200 Medicare services from Dr. Brohl across 5 procedure codes in 2024, for 120 Medicare patients. Medicare paid $17,730 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 120 Medicare patients who saw Dr. Brohl in 2024. The largest group is 75 to 84, with 51 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brohl's median patient age at 72, with 35% women.

In 2024, Dr. Brohl wrote 207 Medicare Part D claims for 52 patients. 65% of them were for generic drugs. CMS names the drug for 97 of them, across 6 drugs with 11 or more claims each, at $334,640 in total drug cost. In 2023, CMS named 84 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Brohl for performance year 2024, reported as part of a group. Dr. Brohl accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brohl as offering telehealth.

Dmand AI links 97 papers to Dr. Brohl, published from 2013 to 2025. 2019 was the busiest year, with 13. The most frequent topics are Carcinoma, Merkel Cell, Sarcoma and Skin Neoplasms. Dr. Brohl has published most often in J Immunother Cancer. Dr. Brohl's most frequent co-authors are Zeynep Eroglu, MD, Damon R. Reed, MD and Nikhil Ishwar Khushalani, MBBS, MD.

Dmand AI links Dr. Brohl to 13 clinical trials, 5 of them phase 1 studies. 11 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Merkel Cell. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 9. Open Payments lists research payments to Dr. Brohl that name 1 trial.

CMS Open Payments shows 42 general payments to Dr. Brohl from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Deciphera Pharmaceuticals Inc. paid the most, $9,902. It also lists 2 research payments totaling $2,932 from 2018 to 2019, naming 1 clinical trial.

Dr. Brohl graduated from University of Miami, Miller School of Medicine in 2006. Dr. Brohl is a member of AOA, AACR and ASCO.

Dr. Brohl is in network with 10 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.